The Pancreatic Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage pipeline products will significantly revolutionize the Pancreatic Cancer market dynamics.

DelveInsight’s “Pancreatic Cancer Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of Pancreatic Cancer, historical and forecasted epidemiology as well as the Pancreatic Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Request a sample for the Pancreatic Cancer Market Report:

https://www.delveinsight.com/report-store/pancreatic-cancer-market

Some of the key facts of the Pancreatic Cancer Market Report:

• The Pancreatic Cancer market size was valued approximately and is anticipated to grow with a significant CAGR during the study period (2022-2036).

• In May 2026, An investigational therapy that could provide new hope for patients with pancreatic cancer has received expanded access authorization from the U.S. Food & Drug Administration (FDA), enabling a broader group of patients to access the drug while clinical studies continue. Pancreatic cancer remains among the most aggressive and difficult-to-treat cancers. The therapy, daraxonrasib (formerly known as RMC-6236), is designed to target mutations in the RAS gene family. Among these, KRAS mutations are the most prevalent, driving more than 90% of pancreatic cancer cases. For decades, researchers considered KRAS mutations largely “undruggable” due to the challenges in effectively targeting them with existing treatments, though recent scientific advances have begun to change that outlook.

• In May 2026, The U.S. Food and Drug Administration (FDA) has authorized Revolution Medicines to move forward with an expanded access program (EAP) for its investigational RAS(ON) inhibitor, daraxonrasib (RMC-6236), in patients with previously treated metastatic pancreatic ductal adenocarcinoma. The program is intended to provide eligible patients who are unable to enroll in clinical trials with access to the therapy. In a separate announcement, Revolution Medicines reported that its Phase III RASolute 302 study evaluating daraxonrasib successfully achieved its primary endpoints. According to the company, patients with previously treated metastatic pancreatic cancer who received daraxonrasib demonstrated a median overall survival of 13.2 months, compared with 6.7 months in patients treated with chemotherapy.

• In March 2026, Revolution Medicines announced that nine oral and poster presentations highlighting advances across its RAS(ON) inhibitor pipeline including daraxonrasib will be featured at the 2026 American Association for Cancer Research (AACR) Annual Meeting.

• In February 2026, Novocure announced that the U.S. Food and Drug Administration (FDA) approved OPTUNE Pax for the treatment of adult patients with locally advanced pancreatic cancer concomitant with gemcitabine and nab-paclitaxel.

• In January 2026, ChipScreen Biosciences received regulatory approval from China’s National Medical Products Administration (NMPA) to initiate a new clinical trial for chiauranib in pancreatic cancer, marking a key advancement following encouraging earlier data.

• In January 2026, Novita Pharmaceuticals, Inc., a privately held clinical-stage biopharmaceutical company focused on developing innovative oncology therapies using its proprietary fascin inhibitor platform, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its investigational small-molecule fascin inhibitor NP-G2-044 for the treatment of pancreatic cancer. Pancreatic cancer remains one of the most lethal cancers, with an estimated five-year survival rate of around 12% and very limited effective treatment options, especially for patients with advanced disease.

• In November 2025, Artios Pharma is advancing a pipeline of oncology therapies, with alnodesertib as its lead candidate, currently under investigation for second-line pancreatic cancer and third-line colorectal cancer. The company announced that it has raised $115 million in a Series D funding round, which will be used to further develop its oncology pipeline. A significant portion of the funds is earmarked for alnodesertib, supporting its ongoing clinical trials in pancreatic and colorectal cancer.

• In November 2025, Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical firm with an extensive portfolio of drug candidates addressing hard-to-treat cancers and viral infections, announced that it has established a research and material transfer agreement with the University of North Carolina at Chapel Hill (UNC). This collaboration will support investigator-initiated preclinical studies assessing Annamycin for the treatment of pancreatic cancer.

• In September 2025, Biostar Pharma, Inc., the U.S. subsidiary of Beijing Biostar Biopharmaceutical Co., Ltd. (2563.HK), a synthetic biology-focused biopharma company developing innovative oncology therapies, announced that its lead pipeline candidate Utidelone has been granted Orphan Drug Designation (ODD) by the U.S. FDA for the treatment of pancreatic cancer. This represents the third ODD awarded to Utidelone, following previous FDA designations for breast cancer brain metastases and gastric cancer.

• In May 2025, UTR Therapeutics Inc. announced the submission of an IND application to the FDA for UTRxM1-18, a novel therapy targeting c-MYC-driven cancers, including triple-negative breast, pancreatic, colorectal, and ovarian cancers. Using its 3’UTR engineering platform, UTRxM1-18 selectively degrades cancer-specific transcripts while sparing healthy cells. In preclinical studies, the therapy demonstrated robust, dose-dependent efficacy across multiple tumor types with no dose-limiting toxicities.

• In April 2025, Verastem Oncology has received FDA clearance for its IND application for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, and intends to initiate a Phase 1/2a clinical trial by mid-year in patients with advanced solid tumors, including pancreatic, colorectal, and non-small cell lung cancers.

• In March 2025, Swedish immunotherapy company Anocca has obtained regulatory approval in four European countries to launch its Phase I/II VIDAR-1 clinical trial, targeting patients with advanced KRAS-positive pancreatic cancer. The study will begin by evaluating ANOC-001, Anocca’s lead candidate, which specifically targets the KRAS G12V mutation, in which glycine at position 12 is substituted with valine.

• In March 2025, Boan Biotechnology (06955.HK) announced that its targeted CD228 antibody-drug conjugate, BA1302, has been granted orphan drug designation (ODD) by the U.S. FDA for the treatment of squamous non-small cell lung cancer and pancreatic cancer.

• As per DelveInsight estimates, exocrine pancreatic cancer is more common than the neuroendocrine pancreatic cancer accounting for more than 90% of total cases.

• According to DelveInsight’s analysis, the total number of incident cases of pancreatic cancer in the US was approximately ~63,700 in 2025.

• According to the analysis, in the US, the majority of pancreatic cancer cases in 2025 were diagnosed at a distant stage (50%), followed by regional (37%) and localized stages (13%), highlighting a concerning trend of late-stage detection.

• DelveInsight estimates that the United States holds the largest market share in 2025 among the 7MM. Chemotherapy regimens remain the dominant standard of care in first-line pancreatic cancer treatment.

• The total market size of pancreatic cancer is expected to increase in the 7MM during the forecast period driven by ongoing clinical research and better diagnostic tools which might improve the prognosis of the disease.

• Key Pancreatic Cancer Companies: AstraZeneca, Merck Sharp & Dohme, Actuate Therapeutics, Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co.Ltd, Carisma Therapeutics Inc, Cue Biopharma, Bold Therapeutics, Purple Biotech Ltd, ENB Therapeutics, Gritstone bio, AstraZeneca, Candel Therapeutics, Alligator Bioscience, FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, and others

• Key Pancreatic Cancer Therapies: LYNPARZA (olaparib), KEYTRUDA (pembrolizumab), Elraglusib (9 ING 41), DF 7001, TNG260, ATA 3271, CMG 901, CT-0508, CUE-102, BOLD-100, CM24, ENB-003, GRT-C903, AZD0171, CAN-2409, Mitazalimab, Pamrevlumab, NIS793, Masitinib, Glufosfamide, and others

• The Pancreatic Cancer epidemiology based on gender analyzed that males are more commonly affected in case of Pancreatic Cancer than females

Pancreatic Cancer Overview

Pancreatic cancer is a type of cancer that originates in the tissues of the pancreas, an organ located behind the stomach that plays a key role in digestion and blood sugar regulation. It often develops silently, showing few early symptoms, which makes it difficult to detect until advanced stages. Common signs may include abdominal pain, jaundice, weight loss, and digestive issues. Pancreatic cancer is aggressive, has a high mortality rate, and treatment options include surgery, chemotherapy, radiation therapy, and targeted therapies, depending on the stage and location of the tumor.

To Know in detail about the Pancreatic Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pancreatic Cancer Market Forecast

Pancreatic Cancer Epidemiology Segmentation:

The Pancreatic Cancer market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Incident Cases of Pancreatic Cancer in the 7MM

• Molecular Alteration-specific Incident Cases of Pancreatic Cancer in the 7MM

• Stage-specific Incident Cases of Pancreatic Cancer in the 7MM

Download the report to understand which factors are driving Pancreatic Cancer epidemiology trends @ Pancreatic Cancer Epidemiological Insights

Pancreatic Cancer Therapies and Key Companies

• LYNPARZA (olaparib): AstraZeneca

• KEYTRUDA (pembrolizumab): Merck Sharp & Dohme

• Elraglusib (9 ING 41): Actuate Therapeutics

• DF 7001: Dragonfly Therapeutics CMG 901 Keymed B

• TNG260: Tango Therapeutics

• ATA 3271: Atara Biotherapeutics

• CMG 901: Keymed Biosciences Co.Ltd

• CT-0508: Carisma Therapeutics Inc

• CUE-102: Cue Biopharma

• BOLD-100: Bold Therapeutics

• CM24: Purple Biotech Ltd

• ENB-003: ENB Therapeutics

• GRT-C903: Gritstone bio

• AZD0171: AstraZeneca

• CAN-2409: Candel Therapeutics

• Mitazalimab: Alligator Bioscience

• Pamrevlumab: FibroGen

• NIS793: Novartis AG

• Masitinib: AB Science

• Glufosfamide: Eleison Pharmaceuticals

To know more about Pancreatic Cancer treatment, visit @ Pancreatic Cancer Medications

Pancreatic Cancer Market Drivers

• Advancements in computational and bioinformatics platforms and several other R&D practices enable the development of Pancreatic Cancer

• Strong pipeline activity

Pancreatic Cancer Market Barriers

• Rising incidence of cancer will provide a larger window of opportunity for new treatments

• Reoccurrence is very common in cancers even after proper treatment; this opens up a new window for pipeline activity

Scope of the Pancreatic Cancer Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Pancreatic Cancer Companies: AstraZeneca, Merck Sharp & Dohme, Actuate Therapeutics, Dragonfly Therapeutics CMG 901 Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co.Ltd, Carisma Therapeutics Inc, Cue Biopharma, Bold Therapeutics, Purple Biotech Ltd, ENB Therapeutics, Gritstone bio, AstraZeneca, Candel Therapeutics, Alligator Bioscience, FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, and others

• Key Pancreatic Cancer Therapies: LYNPARZA (olaparib), KEYTRUDA (pembrolizumab), Elraglusib (9 ING 41), DF 7001, TNG260, ATA 3271, CMG 901, CT-0508, CUE-102, BOLD-100, CM24, ENB-003, GRT-C903, AZD0171, CAN-2409, Mitazalimab, Pamrevlumab, NIS793, Masitinib, Glufosfamide, and others

• Therapeutic Assessment: Pancreatic Cancer current marketed and Pancreatic Cancer emerging therapies

• Pancreatic Cancer Market Dynamics: Pancreatic Cancer market drivers and barriers

• Pancreatic Cancer Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Unmet Needs, KOL’s views, Analyst’s views, Pancreatic Cancer Market Access and Reimbursement

Discover more about therapies set to grab major Pancreatic Cancer market share @ Pancreatic Cancer Treatment Landscape

Table of Contents

1. Pancreatic Cancer Market Report Introduction

2. Executive Summary for Pancreatic Cancer

3. SWOT analysis of Pancreatic Cancer

4. Pancreatic Cancer Patient Share (%) Overview at a Glance

5. Pancreatic Cancer Market Overview at a Glance

6. Pancreatic Cancer Disease Background and Overview

7. Pancreatic Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Pancreatic Cancer

9. Pancreatic Cancer Current Treatment and Medical Practices

10. Pancreatic Cancer Unmet Needs

11. Pancreatic Cancer Emerging Therapies

12. Pancreatic Cancer Market Outlook

13. Country-Wise Pancreatic Cancer Market Analysis (2022–2036)

14. Pancreatic Cancer Market Access and Reimbursement of Therapies

15. Pancreatic Cancer Market drivers

16. Pancreatic Cancer Market barriers

17. Pancreatic Cancer Appendix

18. Pancreatic Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/